

Electronic Supplementary Material (ESI) for New Journal of Chemistry

A facile one-pot synthesis of 2-amino-1, 3, 4-oxadiazole tethered peptidomimetics by molecular-iodine-mediated cyclodeselenization

L. Santhosh, C. Srinivasulu, S. Durgamma, Girish Prabhu and Vommina. V. Sureshbabu*

Room No. 109, Peptide Research Laboratory, Department of Chemistry, Central College Campus, Dr. B. R. AmbedkarVeedhi, Bangalore University, Bangalore 560 001, India.
E-mail: sureshbabuvommina@rediffmail.com, hariccb@gmail.com, hariccb@hotmail.com.

Supporting information

Table of contents

S3.....Experimental procedure for the preparation of 2-amino-1, 3, 4-oxadiazole peptidomimetics 4a-j.

S4-S7.....Characterization data for 2-amino-1, 3, 4-oxadiazole Peptidomimetics 4a-j and Selenosemicarbazide intermediate 3e

S8.....HRMS Spectrum of compound 3e and ^1H NMR Spectrum of Compound 3e

S9..... ^{13}C NMR Spectrum of Compound 3e and ^1H NMR Spectrum of Compound 4a

S10..... ^{13}C NMR Spectrum of 4a and ^1H NMR Spectrum of Compound 4b

S11..... ^{13}C NMR Spectrum of Compound 4b and ^1H NMR Spectrum of Compound 4c

S12..... ^{13}C NMR Spectrum of Compound 4c and ^1H NMR Spectrum of Compound 4d

S13.....¹³C NMR Spectrum of Compound 4d and ¹H NMR Spectrum of Compound 4e

S14.....¹³C NMR Spectrum of Compound 4e and ¹H NMR Spectrum of Compound 4f

S15.....¹³C NMR Spectrum of Compound 4f and ¹H NMR Spectrum of Compound 4g

S16.....¹³C NMR Spectrum of Compound 4g and ¹H NMR Spectrum of Compound 4h

S17.....¹³C NMR Spectrum of Compound 4h and ¹H NMR Spectrum of Compound 4i

S18.....¹³C NMR Spectrum of Compound 4i and ¹H NMR Spectrum of Compound 4j

S19.....¹³C NMR Spectrum of Compound 4j

S20RP-HPLC profiles of compounds 4g and its epimer 4g*

Experimental section

All chemicals were used as obtained from Sigma Aldrich Company, USA. All the solvents were dried and purified using recommended procedures in the literature whenever necessary. High resolution mass spectra were recorded on a Micromass Q-TOF micromass spectrometer using electron spray ionization mode. ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AMX 400 MHz and 100 MHz spectrometer, respectively. Melting points were determined in an open capillary and are uncorrected. TLC experiments were done using MERCK TLC aluminum sheets (silica gel 60 F254) and chromatograms were visualized by exposing in iodine chamber and in UV-lamp. Column chromatography was performed on silica gel (100-200 mesh) using ethyl acetate and hexane mixture as eluent.


General procedure

Synthesis of 2-amino-1, 3, 4-oxadiazole peptidomimetics (4)

To a solution of N^α-protected amino acid hydrazide **1** (1.0 mmol) in THF (8 mL) was added a solution of isoselenocyanato ester **2** (1.0 mmol) and the reaction mixture was stirred for 1-2 h at room temperature till the complete conversion of starting materials (TLC analysis). Then the mixture is cooled to 0 °C and then TEA (2.0 mmol) was added followed by addition of iodine (1.0 mmol) portion-wise over 5 min. Stirring was continued for 15 min and during the reaction precipitation of reddish brown selenium powder was observed. After the reaction was completed (monitored by TLC), the selenium powder was filtered off and washed with THF (10 mL). The combined filtrate was concentrated under vacuum and the residue was diluted with EtOAc and washed with Sat.Na₂S₂O₃, 10% citric acid, 5% Na₂CO₃, brine solution and finally dried over Na₂SO₄, and solvent was evaporated under reduced pressure, the resulting crude product was purified by column chromatography on silica gel (n-hexane-EtOAc = 7:3).


Characterization data:

(S)-methyl-2-((5-((S)-1-(((benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)amino)-3-methylbutanoate (4a)




White solid; yield: 92%; mp 132-133 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -16.3; IR (ν cm⁻¹): 1029, 1233, 1643, 1689, 1742, 2914, 2966, 3011, 3221, 3358; ¹H NMR (400 MHz, CDCl₃) δ : 0.80-0.88 (m, 6H), 1.25 (d, J = 6.8 Hz, 3H), 2.37-2.46 (m, 1H), 3.28 (d, J = 6.4 Hz, 1H), 3.53 (s, 3H), 4.86-4.92 (m, 1H), 5.15 (s, 2H), 6.08 (br s, 1H), 6.45 (br s, 1H), 7.30-7.39 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ : 16.3, 20.7, 29.8, 48.1, 50.1, 62.3, 68.1, 127.9, 128.3, 128.4, 138.4, 156.4, 159.3, 160.5, 171.7; HRMS (ESI): m/z calcd for C₁₈H₂₄N₄O₅Na [M + Na]⁺ 399.1644, found: 399.1638.

(S)-methyl-2-((5-((S)-((tert-butoxycarbonyl)amino)(phenyl)methyl)-1,3,4-oxadiazol-2-yl)amino)-2-phenylacetate (4b)



White solid; Yield: 94%; mp: 123-124 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -2.3; IR (ν cm⁻¹): 1167, 1245, 1365, 1630, 1692, 1749, 2952, 2977, 3033, 3063, 3275, 3369; ¹H NMR (400 MHz, CDCl₃) δ : 1.41 (s, 9H), 3.72 (s, 3H), 5.35 (s, 1H), 5.65 (d, J = 7.2 Hz, 1H), 5.92 (br s, 1H), 6.14 (s, 1H), 7.25-7.38 (m, 10H); ¹³C NMR (100 MHz, CDCl₃) δ : 28.2, 53.1, 59.6, 63.6, 81.5, 126.9, 127.0, 127.2, 128.5, 128.8, 128.9 (2C), 135.7, 137.1, 154.9, 159.9, 162.2, 170.8; HRMS (ESI): m/z calcd for C₂₃H₂₆N₄O₅Na [M + Na]⁺ 461.1801, found 461.1801.


(S)-ethyl-2-((5-((S)-1-(((benzyloxy)carbonyl)amino)-2-phenylethyl)-1,3,4-oxadiazol-2-yl)amino)-4-methylpentanoate (4c)



White solid; Yield: 89%; mp: 141-143 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -23.6; IR (ν cm⁻¹): 1023, 1247, 1286, 1622, 1694, 1724, 2869, 2929, 2956, 3032, 3063, 3245, 3332; ¹H NMR (400 MHz, CDCl₃) δ : 0.95 (d, J = 6 Hz, 6H), 1.28 (t, J = 7.2 Hz, 3H), 1.62-1.74 (m, 3H), 3.10-3.20 (m, 1H), 3.21-3.31 (m, 1H), 4.18-4.23 (m, 2H), 4.32-4.40 (m, 1H), 5.09 (dd, J = 15.6 Hz, J = 12 Hz, 2H), 5.13-5.23 (m, 2H), 5.31 (br s, 1H), 7.10-7.15 (m, 2H), 7.21-7.38 (m, 8H); ¹³C NMR (100 MHz, CDCl₃) δ : 14.2, 21.9, 22.8, 24.8, 39.2, 41.5, 48.7, 54.8, 61.7, 67.1, 127.1,


128.0, 128.2, 128.5, 128.6, 129.4, 129.5, 135.7, 136.2, 155.6, 159.9, 163.1, 173.1; HRMS (ESI): m/z calcd for $C_{26}H_{32}N_4O_5Na [M + Na]^+$ 503.2270, found 503.2270.

(S)-methyl-2-((5-((S)-1-(((benzyloxy)carbonyl)amino)-2-phenylethyl)-1,3,4-oxadiazol-2-yl)amino)-2-phenylacetate (4d)




White solid; Yield: 92%; mp: 140-142 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -28.7; IR (ν cm⁻¹): 1027, 1246, 1636, 1692, 1734, 2924, 2953, 3030, 3063, 3086, 3229, 3312; ¹H NMR (400 MHz, CDCl₃) δ : 3.02-3.25 (m, 2H), 3.75 (s, 3H), 5.07 (dd, J = 18.8 Hz, J = 12 Hz, 2H), 5.16 (s, 1H), 5.21-5.29 (m, 1H), 5.35 (s, 1H), 5.9 (s, 1H), 6.98-7.45 (m, 15H); ¹³C NMR (100 MHz, CDCl₃) δ : 39.2, 53.1, 59.6, 67.1, 127.1, 127.2 (2C), 128.0, 128.1, 128.4, 128.5, 128.9 (2C), 129.0, 129.3, 135.2, 135.4, 135.7, 155.4, 160.1, 162.0, 170.8; HRMS (ESI): m/z calcd for $C_{27}H_{26}N_4O_5Na [M + Na]^+$ 509.1801, found 509.1802.

(S)-methyl-2-((5-((S)-1-((tert-butoxycarbonyl)amino)-2-phenylethyl)-1,3,4-oxadiazol-2-yl)amino)-4-methylpentanoate (4e)



White solid; Yield: 93%; mp: 137-139°C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -25.1; IR (ν cm⁻¹): 1021, 1153, 1247, 1366, 1627, 1693, 1753, 2871, 2955, 3033, 3231, 3370; ¹H NMR (400 MHz, CDCl₃) δ : 0.94 (d, J = 6 Hz, 6H), 1.38 (s, 9H), 1.60-1.75 (m, 3H), 3.07-3.15 (m, 1H), 3.19-3.27 (m, 1H), 3.75 (s, 3H), 4.37-4.40 (m, 1H), 5.0-5.27 (m, 3H), 7.10-7.17 (m, 2H), 7.19-7.31 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 21.9, 22.8, 24.8, 28.3, 39.6, 41.5, 48.1, 52.6, 54.8, 80.2, 127.0, 128.6, 129.5, 135.9, 154.9, 160.2, 163.0, 173.5; HRMS (ESI): m/z calcd for $C_{22}H_{32}N_4O_5Na [M + Na]^+$ 455.2270, found 455.2270.


(S)-methyl-2-((5-((S)-(((benzyloxy)carbonyl)amino)(phenyl)methyl)-1,3,4-oxadiazol-2-yl)amino)-4-methylpentanoate (4f)



White solid; Yield: 91%; mp: 121-123 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -6.7; IR (ν cm⁻¹): 1040, 1153, 1249, 1624, 1688, 1746, 2870, 2955, 3033, 3230, 3299; ¹H NMR (400 MHz, CDCl₃) δ : 0.90 (d, J = 6 Hz, 6H), 1.57-1.78 (m, 3H), 3.70 (s, 3H), 4.30-4.41 (m, 1H), 5.10 (s, 2H), 5.39


(br s, 1H), 6.0-6.12 (m, 2H), 7.21-7.40 (m, 10H); ^{13}C NMR (100 MHz, CDCl_3) δ : 21.8, 22.6, 24.6, 41.6, 51.7, 52.5, 54.7, 67.3, 127.0, 128.1 (2C), 128.4, 128.6, 128.7, 128.9, 129.0, 135.9, 136.8, 155.3, 159.3, 163.2, 173.2; HRMS (ESI): m/z calcd for $\text{C}_{24}\text{H}_{28}\text{N}_4\text{O}_5\text{Na} [\text{M} + \text{Na}]^+$ 475.1957, found 475.1956.

(S)-methyl-2-((5-((S)-1-(((benzyloxy)carbonyl)amino)-2-phenylethyl)-1,3,4-oxadiazol-2-yl)amino)propanoate (4g)




White solid; yield: 90%; mp 171-172 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -21.3; IR (ν cm^{-1}): 1043, 1288, 1635, 1698, 1744, 2933, 2972, 2988, 3028, 3042, 3266, 3318; ^1H NMR (400 MHz, CDCl_3) δ : 1.33 (d, $J = 7.2$ Hz, 3H), 3.09 (d, $J = 7$ Hz, 1H), 3.21 (d, $J = 7$ Hz, 1H), 3.73 (s, 3H), 3.96-4.01 (m, 1H), 5.07 (s, 2H), 5.32-5.37 (m, 1H), 5.85 (br s, 1H), 6.05 (br s, 1H), 7.25-7.42 (m, 10H); ^{13}C NMR (100 MHz, CDCl_3) δ : 15.2, 38.6, 52.1, 54.2, 58.4, 64.2, 127.1, 127.8, 128.2, 128.6, 129.4, 129.7, 137.2, 138.2, 156.3, 158.6, 163.8, 171.9; ESI-MS: m/z calcd for $\text{C}_{22}\text{H}_{24}\text{N}_4\text{O}_5\text{Na} [\text{M} + \text{Na}]^+$ 447.1644, found: 447.1642.

(2S,3R)-methyl-2-((5-((S)-1-(((benzyloxy)carbonyl)amino)-2-phenylethyl)-1,3,4-oxadiazol-2-yl)amino)-3-methylpentanoate (4h)



White solid; Yield: 91%; mp: 116-118 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -10.3; IR (ν cm^{-1}): 1024, 1244, 1284, 1621, 1688, 1737, 2877, 2923, 2962, 3032, 3061, 3246, 3326; ^1H NMR (400 MHz, CDCl_3) δ : 0.88-0.97 (m, 6H), 1.16-1.31 (m, 2H), 1.94-2.04 (m, 1H), 3.11-3.19 (m, 1H), 3.23-3.28 (m, 1H), 3.76 (s, 3H), 5.08 (dd, $J = 20.8$ Hz, $J = 12.8$ Hz, 2H), 5.15-5.22 (m, 1H), 5.26-5.41 (m, 3H), 7.11-7.36 (m, 10H); ^{13}C NMR (100 MHz, CDCl_3) δ : 11.6, 14.2, 26.1, 37.6, 48.5, 52.4, 59.6, 60.6, 67.1, 127.0, 128.0, 128.1, 128.5, 128.6, 129.3, 135.4, 135.5, 155.4, 159.8, 163.4, 172.6; HRMS (ESI): m/z calcd for $\text{C}_{25}\text{H}_{30}\text{N}_4\text{O}_5\text{Na} [\text{M} + \text{Na}]^+$ 489.2114, found 489.2112.


(S)-ethyl-2-((5-((1S,2S)-1-(((benzyloxy)carbonyl)amino)-2-methylbutyl)-1,3,4-oxadiazol-2-yl)amino)-2-phenylacetate (4i)



White solid; Yield: 92%; mp: 143-144 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -35.1; IR (ν cm^{-1}): 1026, 1152, 1249, 1625, 1693, 1750, 2871, 2956,


3033, 3233, 3307; ^1H NMR (400 MHz, CDCl_3) δ : 0.83-0.90 (m, 6H), 1.03-1.18 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H), 1.35-1.48 (m, 1H), 4.20-4.27 (m, 2H), 4.51 (br s, 1H), 4.68 (s, 1H), 5.10 (dd, J = 15.3 Hz, J = 12.1 Hz, 2H), 5.35 (d, J = 6.8 Hz, 1H), 6.07 (br s, 1H), 7.27-7.44 (m, 10H); ^{13}C NMR (100 MHz, CDCl_3) δ : 11.3, 13.9, 15.0, 24.8, 38.4, 51.9, 59.7, 62.3, 67.1, 127.1, 128.1 (2C), 128.4, 128.7 (2C), 128.8, 128.9, 136.0, 155.7, 159.9, 161.9, 170.4; HRMS (ESI): m/z calcd for $\text{C}_{25}\text{H}_{30}\text{N}_4\text{O}_5\text{Na} [\text{M} + \text{Na}]^+$ 489.2114, found 489.2113.

(S)-methyl-2-((5-((S)-1-((tert-butoxycarbonyl)amino)-2-phenylethyl)-1,3,4-oxadiazol-2-yl)amino)-3-phenylpropanoate (4j)




White solid; yield: 94%; mp: 146-148 °C; $[\alpha]^{26}_D$ (c 1.0, MeOH) -17.1; IR (ν cm^{-1}): 1112, 1266, 1645, 1698, 1745, 2958, 2966, 3033, 3068, 3075, 3258, 3383; ^1H NMR (400 MHz, CDCl_3) δ : 1.39 (s, 9H), 3.08-3.31 (m, 4H), 3.75 (s, 3H), 4.66 (d, J = 6.4 Hz, 1H), 5.09 (br d, J = 6.8 Hz, 1H), 5.19 (br s, 1H), 6.51 (br s, 1H), 7.05-7.30 (m, 10H); ^{13}C NMR (100 MHz, CDCl_3) δ : 28.3, 37.7, 39.6, 48.1, 52.7, 56.8, 80.8, 127.1, 127.4, 128.6, 128.7, 129.4, 129.5, 135.3, 135.8, 154.9, 160.4, 162.3, 171.6; HRMS (ESI): m/z calcd for $\text{C}_{25}\text{H}_{30}\text{N}_4\text{O}_5\text{Na} [\text{M} + \text{Na}]^+$ 489.2114, found: 489.2114.


(2S, 8S)-methyl-8-benzyl-2-isobutyl-12,12-dimethyl-7,10-dioxo-4-selenoxo-11-oxa-3,5,6,9-tetraazatridecan-1-oate (3e)




^1H NMR (400 MHz, CDCl_3) δ : 0.93-0.96 (m, 6H), 1.40 (s, 9H), 1.66-1.90 (m, 3H), 2.92-3.02 (m, 1H), 3.20-3.26 (m, 1H), 3.69 (s, 3H), 4.29 (br s, 1H), 5.01-5.19 (m, 2H), 7.21-7.35 (m, 5H), 7.73 (br s, 1H), 8.54 (br s, 1H), 9.04 (br s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 21.6, 21.8, 22.8, 28.2, 37.3, 40.3, 52.4, 56.2, 58.8, 81.2, 127.0, 128.7, 129.0, 129.2, 136.5, 155.9, 170.3, 173.1, 181.7; HRMS (ESI): m/z calcd for $\text{C}_{22}\text{H}_{34}\text{N}_4\text{O}_5\text{SeNa} [\text{M} + \text{Na}]^+$ 537.1592, found: 537.1593.




HRMS Spectrum of **3e**




¹H NMR spectrum of **3e**




^{13}C NMR spectrum of **3e**




^1H NMR spectrum of **4a**




¹³C NMR spectrum of **4a**




¹H NMR spectrum of **4b**




^{13}C NMR spectrum of **4b**




^1H NMR spectrum of **4c**




¹³C NMR spectrum of **4c**




¹H NMR spectrum of **4d**




¹³C NMR spectrum of **4d**




¹H NMR spectrum of **4e**




^{13}C NMR spectrum of **4e**




^1H NMR spectrum of **4f**




¹³C NMR spectrum of **4f**




¹H NMR spectrum of **4g**




¹³C NMR spectrum of **4g**




¹H NMR spectrum of **4h**




¹³C NMR spectrum of **4h**




¹H NMR spectrum of **4i**




¹³C NMR spectrum of **4i**




¹H NMR spectrum of **4j**



^{13}C NMR spectrum of **4j**



Cbz-Phe- ψ -[C₂N₂O]-NH-L-Ala-OMe **4g**



Cbz-Phe- ψ -[C₂N₂O]-NH-D-Ala-OMe **4g***

RP-HPLC profiles of Cbz-Phe- ψ -[C₂N₂O]-NH-L-Ala-OMe (**4g**) and Cbz-Phe- ψ -[C₂N₂O]-NH-D-Ala-OMe (**4g***) (method: gradient 0.1% TFA water-acetonitrile; acetonitrile 30-100% in 30 min; VWD at $\lambda = 254$ nm; flow rate: 0.5 mL/min; column: Agilent Eclipse, XDB-C18, pore size-5 μ m, diameter x length = 4.6 x 150 nm).